Search
Sinoway Announces Approval of Subsidiary's Dupilumab Injection Clinical Trial
2025-08-19 /
Read about 0 minute
Author：小编
Sinoway's subsidiary, Jushi Biotech, has recently secured approval from the National Medical Products Administration for the initiation of clinical trials on Dupilumab Injection. This biosimilar of Dupixent® targets IL-4Rα and is intended for the treatment of moderate to severe atopic dermatitis in adult patients. The clinical trials are set to commence shortly.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
